Arkolith/Insider Trading/TRVI/Form 4

Sciascia Thomas

Chief Scientific OfficerTrevi Therapeutics, Inc. (TRVI) · full profile →Form 4 · filed May 31, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$136K
Net Open-Market Flow
-$136K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 29, 2024Sell(S)53K$2.55$136K214K
May 29, 2024Option exercise(M)59K$2.19$130K268K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 29, 2024Option exercise(M)59K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-067305) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML